About Orthogonal Biologics
Orthogonal Biologics is a Healthcare company based in United States founded in 2020, and was acquired by Cyrus Biotechnology in December 2021. Protein drug manufacturing and research services are provided. Its chief executive, as recorded, is Erik Procko. Its focus areas include Biopharma Outsourcing, Diversified and Biologics. Its competitors include Catalent, Surrozen and Curia; 1 of its 3 listed competitors has raised funding.
Company details
Orthogonal Biologics was founded in 2020 and is based in the United States. Operations focus on the biotechnology sector, where manufacturing and research services for protein drugs are offered. These services support drug development processes, including production and scientific investigation. The company is led by CEO Erik Procko, with activities centered on advancing biologic therapies through specialized expertise.
- Headquarters United States
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website orthogonalbiologics.com
- Social X Facebook
- Acquired by Cyrus Biotechnology (Dec 2021)
- Investors
- Acquired byCyrus Biotechnology
(Dec 2021)
Investors in Orthogonal Biologics
Orthogonal Biologics has secured backing from 1 investor. Prominent investors backing the company include Cyrus Biotechnology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cloud-based protein-modeling software is developed for drug discovery. | 2014 | cyrusbio.com | Seattle, United States |
Investor details for Orthogonal Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Orthogonal Biologics
1 people are tracked at Orthogonal Biologics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Erik Procko | CEO | Leadership |
Complete people profiles for Orthogonal Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Orthogonal Biologics
2 dated milestones of Orthogonal Biologics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Orthogonal Biologics is founded.
- Exit Acquired by Cyrus Biotechnology.
Competitors of Orthogonal Biologics
Orthogonal Biologics has 3 listed competitors in our database, 1 of them funded. They include Catalent, Surrozen and Curia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| catalent.com | 2007 | Somerset, United States | 9,390 | CDMO offering drug and biologics development services | ||
| surrozen.com | 2016 | San Francisco, United States | $133M | 80 | Selective Wnt agonists are developed for human tissue regeneration. | |
| curiaglobal.com | 1991 | Albany, United States | 1,918 | Drug research, development, testing, and consulting services are provided. |
Detailed competitors of Orthogonal Biologics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Orthogonal Biologics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Orthogonal Biologics
Orthogonal Biologics was founded in 2020.
Orthogonal Biologics is headquartered in United States.
Erik Procko is the CEO of Orthogonal Biologics, as recorded in our data.
Orthogonal Biologics was founded in 2020 and is based in the United States. Operations focus on the biotechnology sector, where manufacturing and research services for protein drugs are offered. These services support drug development processes, including production and scientific investigation. The company is led by CEO Erik Procko, with activities centered on advancing biologic therapies through specialized expertise.
Orthogonal Biologics has 1 investor. Key investors include Cyrus Biotechnology.
Yes. Orthogonal Biologics was acquired by Cyrus Biotechnology in December 2021.
